CASI Pharmaceuticals, Inc (CASI) Stock Price

1.32 ▼ -0.07 (-5.04%)
Open: 1.35 Vol: 0 Day's range: 1.32 - 1.35 Nov 04, 15:14 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
CASI Technical Analysis
5 mins 30 mins Hourly Daily Weekly
SELL SELL SELL SELL SELL
  5 mins 30 mins Hourly Daily Weekly
MA5 1.35▼ 1.35▼ 1.36▼ 1.39▼ 1.62▼
MA10 1.37▼ 1.37▼ 1.38▼ 1.51▼ 1.77▼
MA20 1.45▼ 1.48▼ 1.49▼ 1.68▼ 1.71▼
MA50 1.57▼ 1.61▼ 1.62▼ 1.86▼ 2.09▼
MA100 1.66▼ 1.74▼ 1.76▼ 1.72▼ 3.64▼
MA200 1.80▼ 1.72▼ 1.84▼ 1.94▼ 3.57▼
  5 mins 30 mins Hourly Daily Weekly
MACD -0.006▼ -0.010▼ -0.012▼ -0.034▼ -0.008▼
RSI 28.825▼ 30.380▼ 30.289▼ 32.348▼ 39.528▼
STOCH 15.278▼ 4.696▼ 4.633▼ 6.559▼ 28.613    
WILL %R -100.000▼ -100.000▼ -100.000▼ -100.000▼ -94.149▼
CCI -147.529▼ -93.782     -85.479     -136.404▼ -126.091▼
Latest Filters Detected On CASI
▼ GAP $CASI Open Gap Down %2 Set Alert
▼ BREAK $CASI Price Breaks 20 Days Low Set Alert
▼ BREAK $CASI Price Breaks 10 Days Low Set Alert
CASI Pharmaceuticals, Inc News
CASI Pharmaceuticals to Participate at Guggenheim Healthcare Innovation Conference
Tuesday, November 04, 2025 06:12 AM
SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / November 4, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential ...
CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology Annual Meeting
Monday, November 03, 2025 06:03 AM
CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody - Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / ...
CASI Pharmaceuticals Announces Upcoming Presentation of Clinical Results for CID-103 at the 67th American Society of Hematology (ASH) Annual Meeting
Monday, November 03, 2025 05:07 AM
Title: A dose-escalation and safety study of CID-103 followed by a randomized, open-label, parallel-arm multi-dose study evaluating the efficacy and tolerability of CID-103 in adults with persistent ...
CASI historical stock data
date open high low close volume
04/11/25 1.35 1.35 1.32 1.32 18,525
03/11/25 1.46 1.46 1.37 1.39 18,031
31/10/25 1.44 1.44 1.37 1.44 19,215
30/10/25 1.52 1.5438 1.345 1.36 64,631
29/10/25 1.62 1.7002 1.41 1.42 56,725
28/10/25 1.64 1.73 1.55 1.58 27,225
27/10/25 1.64 1.67 1.6065 1.62 17,401
24/10/25 1.61 1.77 1.61 1.64 11,898
23/10/25 1.64 1.8899 1.61 1.61 49,913
22/10/25 1.74 1.8799 1.60 1.68 28,741
Quote Details
52wk Low:1.091
52wk High:5.95
Vol:0
Avg Vol(3m):2.4M
1Y Chng:-75.23%
1M Chng:-16.46%
Add to Watch List
More Information
Index US Composite
Market Cap. 22.31M